TRAW (Traws Pharma) Cyclically Adjusted PS Ratio: (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAW Traws Pharma Inc TRAW
44 GF Score
Price $0.65
GF Value $12.97
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma  (NAS:TRAW) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Traws Pharma Cyclically Adjusted PS Ratio Related Terms


Traws Pharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Cyclically Adjusted PS Ratio Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.03 0.04 0.02 0.00

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

TRAW vs ICU, INAB, CALC: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PS Ratio falls into.


TRAW
44GF Score
Traws Pharma Inc TRAW
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Traws Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Traws Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Traws Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 1,651.000 241.428 2,258.154
201612 173.000 241.432 236.617
201703 210.000 243.801 284.432
201706 162.000 244.955 218.385
201709 55.000 246.819 73.583
201712 71.500 246.524 95.773
201803 188.000 249.554 248.764
201806 44.091 251.989 57.778
201809 8.000 252.439 10.465
201812 3.933 251.233 5.169
201903 4.250 254.202 5.521
201906 126.375 256.143 162.919
201909 3.938 256.759 5.065
201912 0.101 256.974 0.130
202003 0.121 258.115 0.155
202006 0.124 257.797 0.159
202009 0.137 260.280 0.174
202012 0.115 260.474 0.146
202103 0.096 264.877 0.120
202106 0.090 271.696 0.109
202109 0.089 274.310 0.107
202112 0.067 278.802 0.079
202203 0.067 287.504 0.077
202206 0.068 296.311 0.076
202209 0.068 296.808 0.076
202212 0.067 296.797 0.075
202303 0.067 301.836 0.073
202306 0.068 305.109 0.074
202309 0.068 307.789 0.073
202312 0.067 306.746 0.072
202403 0.067 312.332 0.071
202406 0.056 314.175 0.059
202409 0.059 315.301 0.062
202412 0.015 315.605 0.016
202503 0.008 319.799 0.008
202506 0.470 322.561 0.481
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.65 is trading 95% below its estimated GF Value™ of $12.97. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $12.97 vs. price of $0.65 (95% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
44GF Score

Get the complete analysis for TRAW

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$12.97
GF Value